Lakefront Biotherapeutics (LKFT) Inventory (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Inventory data on file, last reported at $20.7 million in Q1 2026.

• Inventory for Q1 2026 came in at $20.7 million, down 48.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.7 million (down 48.87% YoY), and the FY2025 annual result was $26.2 million, down 52.14% from the prior year.
• Inventory retreated to $20.7 million in Q1 2026 per LKFT's latest filing, from $26.2 million in the prior quarter.
• Over five years, Inventory peaked at $87.5 million in Q1 2024 and troughed at $20.6 million in Q1 2022.
• A 5-year average of $49.0 million and a median of $54.0 million in 2022 frame the typical range for Inventory.
• The sharpest annual moves came in 2023 and 2025: Inventory surged 169.11% in 2023, then slumped 62.74% in 2025.
• A 5-year view of Inventory shows it stood at $54.0 million in 2022, then surged by 47.41% to $79.6 million in 2023, then slumped by 31.27% to $54.7 million in 2024, then slumped by 52.14% to $26.2 million in 2025, then decreased by 20.89% to $20.7 million in 2026.
• Business Quant data shows LKFT's Inventory at $20.7 million in Q1 2026, $26.2 million in Q4 2025, and $26.8 million in Q3 2025.